[ad_1]
Mexico .- Recurrent multiple sclerosis can be solved through a revolutionary oral treatment that promises to reduce epidemics by 67% and up to four years, said a specialist at Efe.
"This is a new effective oral therapy for MS patients, which helps in the transmission of the disease and slows down the disabling effects without the need for it." Administer continuous treatment or frequent follow-up, "said Luciano Rossetti, executive vice president of Merck Pharmaceutical Product.
The therapy, he explained, is short-lived because it is reduced to two short-term oral treatments for four years, which means fewer days of treatment.
Multiple sclerosis is an autoimmune, chronic and inflammatory disease in which the immune system attacks myelin, an insulating coating around nerve cells in the brain and / or spinal cord, taken as a foreign substance.
] This is an incurable disease that affects more than 2.3 million people worldwide, 85% of whom have a recurring form.
In Latin America, this figure reaches between 50,000 and 100,000 patients, while in Mexico, about 20,000 people are affected by this disease.
Merck Pharmaceutical created this drug, known as cladribine tablets, specifically for the treatment of people with a very active EMR, with frequent epidemics and progression of disability.
However, it will not be a drug. first choice will not be made available to all concerned.
"This new treatment is considered a very effective drug because it dramatically reduces the number of outbreaks and slows the progression of disability," said Merck's global director and development.
According to Rossetti, this new drug is the first disease modifier capable of controlling this disease for four years, with a maximum oral dose of 20 days in the first two years.
In addition to putting the disease in remission, patients will have the opportunity to benefit from this shorter treatment, which will also mean savings.
"One of the major effects of this disease is economic because medication, relapse and progression of disability entail high costs," said Rossetti.
It is estimated that 70% of multiple sclerosis cases occur between the ages of 20 and 40, affecting the quality of life of young adults in the most productive phase of their lives.
Added to this is the fact that 25% of patients will need a wheelchair 15 years after diagnosis.
In addition, the DMEE can invalidate the patient and leave him unemployed, since about 50% of patients with this disease lose their job between 3 and 10 years after diagnosis.
Rossetti badured that the effectiveness of this new treatment had been demonstrated in three clinical trials involving 2,700 patients.
"In patients with high disease activity, two-year CLARITY Phase III clinical trial badyzes showed that cladribine tablets reduced the annualized rate of outbreaks by 67% and the risk confirmed progression of EDSS (Expanded Scale) disability at 6 months of 82% compared to placebo, "he explained.
Side effects of this new drug include a reduction in the number of lymphocytes, infections, and an increased risk of malignancy.
This drug is contraindicated in pregnant women, people with chronic active infection, for example tuberculosis or hepatitis, HIV, severe or moderate kidney or liver disease.
Considering that women of childbearing age should avoid pregnancy during treatment and at least 6 months after the last dose of the year
Rossetti badured that the treatment had already been approved in over 40 countries, among it is Canada, Argentina, Chile and part of the European Union, and it will be in the coming months, Mexico and Latin America .
Source link
